Interim results from cohort 1 of the double-blind, dose-escalation phase i/ii clinical trial of amt-130 (hd-genetrx-1) for early-stage huntington's disease (hd)Erin Furr Stimming,Victor Sung,Claudia Testa,Sandra Kostyk,Christopher A. Ross,Ali Samii,Michael D. Geschwind,Deborah Hall,Praveen Dayalu,Russell Lonser, Brad Elder,Paul S. Larson,David L. Cooper,Marcie Clarkin,Talaha M. Ali,Ricardo E. DolmetschJ: Clinical therapeutics（2022）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
